Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¾Ï ȯÀÚ¿¡¼­ EGFRÀÇ ¿¹ÈÄÀû °¡Ä¡ The Prognostic Value of Epidermal Growth Factor Receptor in Primary Breast Cancer

´ëÇѾÏÇÐȸÁö 1998³â 30±Ç 4È£ p.711 ~ 718
¹ÚºÀ±Ù, Â÷¼ºÀç, ¹Ú¼ºÁØ,
¼Ò¼Ó »ó¼¼Á¤º¸
¹ÚºÀ±Ù (  ) 
Áß¾Ó´ëÇб³ ºÎ¼Óº´¿ø ¿Ü°úÇб³½Ç

Â÷¼ºÀç (  ) 
Áß¾Ó´ëÇб³ ºÎ¼Óº´¿ø ¿Ü°úÇб³½Ç
¹Ú¼ºÁØ (  ) 
Áß¾Ó´ëÇб³ ºÎ¼Óº´¿ø ¿Ü°úÇб³½Ç

Abstract

¼­·Ð
À¯¾ÏÀÇ ¿¹ÈÄ´Â °³Àο¡ µû¶ó »ó´çÈ÷ ´Ù¾çÇϸç, ¼ö¼ú ÈÄ Àç¹ß ¹× »ýÁ¸À²À» Á»´õ Á¤È®È÷ ¿¹
ÃøÇϱâ À§ÇØ ¿©·¯ °¡Áö ¿¹ÈÄÀÎÀÚµéÀÌ »ç¿ëµÇ°í ÀÖ´Ù. ÀÌµé ¿¹ÈÄÀÎÀڷδ Á¾¾çÀÇ Å©±â, ¾×¿Í
¸²ÇÁÀý ÀüÀÌÀ¯¹«, ½ºÅ×·ÎÀÌµå ¼ö¿ëü»óÅÂ, º´¸®ÇÐÀû ºÐÈ­µµ, DNAÇÔ·®ºÐ¼® µîÀ» µé ¼ö ÀÖ´Ù.
ÃÖ±Ù¿¡ µé¾î ¾Ï¼ºÀåÀÎÀÚ¿Í ¾ÏÀ¯ÀüÀÚ¿¡ ´ëÇÑ ¿¬±¸°¡ È°¹ßÇØÁö°í ÀÖÀ¸¸ç, À¯¾ÏÀÇ ¾ÏÈ­°úÁ¤¿¡
°ü¿©ÇÑ´Ù°í ¾Ë·ÁÁ® Àִ ǥÇǼºÀåÀÎÀÚ(Epidermal growth factor, EGF·Î ¾àÇÔ)¿¡ ´ëÇÑ ¿¬±¸
°¡ ÀÌ·ç¾îÁö°í ÀÖ´Ù. ÀÌ´Â Á¤»ó ¼¼Æ÷ ¼ºÀå¿¡ °ü¿©ÇÏ´Â polypeptide·Î, À¯¾ÏÀÇ ¾ÏÈ­°úÁ¤¿¡ °ü
¿©ÇÑ´Ù°í ¾Ë·ÁÁ® ÀÖ´Ù. À¯¾Ï¼¼Æ÷¿¡ À־ Ç¥ÇǼºÀåÀÎÀÚÀÇ ¼ºÀåÀÚ±ØÀº Ç¥ÇǼºÀåÀÎÀÚ¼ö¿ëü
(Epidermal growth factor receptor, EGFR·Î ¾àÇÔ)¸¦ ¸Å°³ÇÏ¿© ÀÌ·ç¾îÁö¸ç, ÀÌÀÇ autocrine
mechanismÀÌ À¯¾Ï¼¼Æ÷ÀÇ ¹ß¾Ï°úÁ¤°ú µ¶¸³ÀûÀÎ ¼ºÀå¿¡ Á߿俪ÇÒÀ» ÇÑ´Ù°í ÇÑ´Ù.
ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº À¯¾ÏȯÀÚÀÇ ¼ö¼ú ÈÄ Á¶Á÷¿¡¼­ EGFR¿¡ ´ëÇÑ ¸é¿ªÁ¶Á÷ÇÐÀû ¿°»öÀ» ½Ç½Ã
ÇÏ¿© EGFRÀÇ Á¸ÀçÀ¯¹«¸¦ ¾Ë¾Æº¸°í, À̸¦ ¿¡½ºÆ®·Î°Õ ¼ö¿ëü(Estrogen receptor, ER·Î ¾à
ÇÔ), À¯¾ÏÀÇ ´Ù¸¥ ¿¹ÈÄÀÎÀÚµé, ±×¸®°í Àç¹ß·ü°úÀÇ »ó°ü°ü°è¸¦ ºñ±³ÇØ º½À¸·Î½á, EGFRÀÇ ¿¹
ÈÄÀÎÀڷμ­ÀÇ °¡Ä¡¿¡ ´ëÇØ ¾Ë¾Æº¸·Á´Â °ÍÀÌ´Ù.
#ÃÊ·Ï#
Purpose: The objective of this study was to ascertain the relationship between
epidermal growth factor receptor(EGFR) status and estrogen receptor(ER) and other
prognostic factors in primary human breast cancer patients. We tried to evaluate the
value of EGFR as a prognostic factor.
Materials and Methods: EGFR and ER were measured by immunohistochemical
staining. It was performed on section from paraffin blocks of 60 primary breast cancer
patients who underwent mastectomy at Chung-Ang University Hospital. And we
evaluate the relationship between EGFR and ER and other prognostic factors.
Results: In 20 of 60 patients(33.3%), the staining was positive for the expression of
EGFR. Of the 60 patients, 6 were both positive for EGFR and ER, 25 were both
negative, 14 were EGFR positive and ER negative, 15 were EGFR negative and ER
positive. Between EGFR and estrogen receptor(ER) status, previously known clear
inverse relationship was not observed in our study. The EGFR status was not correlated
with axillary lymph node involvement, histologic type, and histologic grading. But it was
correlated with tumor size(p=0.049), and there was a high tendency of recurrence rate of
patients with EGFR-positive tumors as compared with those with EGFR-negative
tumors(p=0.078).
Conclusion: EGFR status may be valuable as a prognostic factor in determining the
prognosis of breast cancer. However, the study of more cases will be needed for the
significance of the information about the EGFR as an independent prognostic factor.

Å°¿öµå

Epidermal growth factor receptor(EGFR); Estrogen receptor(ER); Breast cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS